Trending...
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
RALEIGH, N.C., April 16, 2021 /PRNewswire/ -- Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
- Merger Advancement For Embodied AI Co in Robotic Systems Serving High Value Hospitality, Gaming & Real Estate Sectors: MBody AI Corp. (NAS DAQ: MBAI)
- Hollywood In Pixels Announces Honorees for The 9th Silver PIXel Awards
- New Research Finds a Good Deal Is All It Takes to Get Americans Booking a Last-Minute Vacation — and Most Already Have One on Their Mind
- GitKraken Introduces GitLens 19, Bringing Human and AI Workflows Together in One Workbench
- LĪNA Universal Balm Nominated for "Best Clean Skincare Product" at CertClean Beauty Awards
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
- Bronze Stevie Award Recognizes Satyadhar Joshi for AI Research and Public Policy Engagement
- Plumber Pros of Clayton NC Opens as Johnston County's #1-Rated Plumbing Choice
- synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
- Leading PDR Training Courses in Canada: Learn Paintless Dent Repair with PDR Academy & Tint Academy
- Five Years of Scattering Joy: Gioia dell'Amore Cellars Celebrates Five Years of Wine, Love & a Drea
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- OPUS Global Data Solutions Launches Food Trader Plus, Bringing Operational Control and Deal-Level Profit Visibility to Food Brokers
- Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
- Michael Maertens Hired as Century Fasteners Corp. – Chief Financial Officer
- Beneath the Cloudline Explores Hope After Collapse in a New YA Science-Fantasy Novel
- Built to Last: Why BSI Is Among the Nation's Fastest-Growing Companies, and One of Its Best Places to Work
- Bent Danholm's The Architecture of Demand Reaches No. 2 in Amazon Real Estate Sales
- Contracting Resources Group Named to Inc. 5000 for the Ninth Time
- ImagineX Named to 2026 Inc. 5000 List of America's Fastest-Growing Private Companies
- ASSIST Software Becomes One of the First European Companies Certified to ISO/IEC 42001
- The World's No.1 Superstar® Enters the Occult with New Track and Cinematic Visual "Under Your Spell"
- PricZone Launches Online Shopping Platform Offering Electronics, Gaming, and More
- Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community
- Lineus Medical Elevates Leadership to Accelerate Growth After Breakthrough Clinical Results
- Gateway Center Arena Announces Duane Curry as General Manger
- New from Regal House Publishing, The Parliament of Mice, classic animal fables retold as satires
- XRPPower Expands Platform Security With Enhanced Brand Protection and Official Verification Standards
- Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
- RAS AP Consulting Expands Managed AP Governance™ Ecosystem, Launches Trademark Process, and Secures IFOL Speaker Invitation
- UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
- International Rights Groups Raise Alarm Over Freedom of Religion and Expression in South Korea